Zacks: Brokerages Set $12.25 Price Target for Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX)
Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokers have set a 1 year consensus price target of $12.25 for the company and are anticipating that the company will post $0.12 earnings per share for the current quarter, according to Zacks. Zacks has also given Cumberland Pharmaceuticals an industry rank of 83 out of 256 based on the ratings given to its competitors.
Separately, Zacks Investment Research downgraded shares of Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 13th.
In other Cumberland Pharmaceuticals news, Director Gordon R. Bernard sold 4,000 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $6.36, for a total value of $25,440.00. Following the completion of the transaction, the director now owns 86,319 shares in the company, valued at $548,988.84. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gordon R. Bernard sold 7,471 shares of the company’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $5.77, for a total transaction of $43,107.67. Following the completion of the transaction, the director now owns 59,673 shares of the company’s stock, valued at approximately $344,313.21. The disclosure for this sale can be found here. Over the last 90 days, insiders have purchased 8,101 shares of company stock valued at $51,063 and have sold 55,111 shares valued at $337,807. Insiders own 39.38% of the company’s stock.
Several institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC raised its position in shares of Cumberland Pharmaceuticals by 13.0% in the second quarter. Renaissance Technologies LLC now owns 441,577 shares of the specialty pharmaceutical company’s stock worth $2,813,000 after acquiring an additional 50,800 shares during the period. BlackRock Inc. raised its position in shares of Cumberland Pharmaceuticals by 17.2% in the second quarter. BlackRock Inc. now owns 332,543 shares of the specialty pharmaceutical company’s stock worth $2,118,000 after acquiring an additional 48,753 shares during the period. Acadian Asset Management LLC raised its position in shares of Cumberland Pharmaceuticals by 6.9% in the second quarter. Acadian Asset Management LLC now owns 104,498 shares of the specialty pharmaceutical company’s stock worth $665,000 after acquiring an additional 6,765 shares during the period. Finally, Bailard Inc. acquired a new position in shares of Cumberland Pharmaceuticals in the second quarter worth about $92,000. Institutional investors and hedge funds own 30.29% of the company’s stock.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.
Featured Story: Quick Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.